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Abstract 
Background: Zolpidem is a non-benzodiazepine medication which selectively affects GABA A receptors and 
treats insomnia. There are numerous reports of psychosis following the consumption of zolpidem all of which 
recovered after stopping the medication. 
Case Report: A 27 year old male law student, who was treated with 10 mg zolpidem due to insomnia, 
increased the dosage to 500 mg during 3 months. Not only was his insomnia remained untreated, but also he 
gradually became isolated, suspicious, and aggressive, and dropped out of university. He was then 
hospitalized in a psychiatric ward for 2 months, and was treated with antipsychotics and gradual 
discontinuation of zolpidem. With no improvement in psychosis and sleep improvement he was discharged. 
After two weeks he was hospitalized again and went under electroconvulsive therapy (ECT) and antipsychotic 
therapy, and was discharged with relative improvement. Now, after three years, he is diagnosed with 
schizophrenia and with modest improvements he is under care and treatment. 
Conclusion: Zolpidem is a fairly useful medication for treating sleep problems, especially improving 
beginning of sleep. However, physicians  and clinicians should consider the conditions, predispositions, and 
personal and family history of types of psychosis, alcohol and drug abuse in the comprehensive assessment 
and treatment plan for patients with insomnia. 
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Introduction 
Zolpidem is one of the effective non-
benzodiazepine medications for treatment of 
insomnia,  which so-called Z-drugs . This drug, 
unlike benzodiazepines that activate all three 
specific binding sites of GABA, activates GABA 
receptors, causes the opening of chloride channels, 
reduces the firing rate of neurons and muscle 
fibers, and selectively binds to the subunit-specific 
GABA receptors. For this reason, it less sedation, 
muscle relaxation, and anticonvulsant effect 
compared to benzodiazepines, while it is  
sleep-improving medication.1,2 After oral 
administration, this drug is rapidly absorbed, but if 
consumed with food, absorption is delayed by an 
hour. During 1.6 hours it reaches its peak plasma 
concentration and has a half-life of 2.6 hours.3  
Rapid metabolism and lack of active zolpidem 
metabolites prevent the accumulation of potentially 
toxic compounds. This is also something that is 
contrary to the long-term use of drugs affecting 
benzodiazepine receptors.4 The drug metabolism in 
the liver occurs by a wide range of cytochrome 
isoenzymes through oxidation and hydroxidation. 
In addition, 48 to 67% of products resulting from 
zolpidem metabolism are excreted in the urine and a 
less amount is excreted in the bile, and in the elderly 
it is less clear.1,5  
Zolpidem is an effective drug for treatment of 
short-term insomnia. Clinically, the drug is 
effective, safe, and well tolerated. It has been 
reported that patients do not develop tolerance to 
zolpidem, insomnia and withdrawal syndrome 
after discontinuation of medication has not been 
observed, and the risk of drug abuse and 
dependence is minimal. However, cases of 
dependence and abuse have been reported. 
Patients with a history of drug abuse and drug 
dependence are at risk of dependence on this drug. 
Therefore, in prescribing this drug, like prescribing 
drugs affecting benzodiazepine receptors, caution 
should be exercised.6,7 Zolpidem is used as a 
treatment for insomnia and can sometimes have 
irreparable effects. There are many reports of 
transient psychosis following the use of zolpidem, 
and patients recovered with drug withdrawal in 
these situations.2  
Case Report 
A 21 year old male law student was treated with  
zolpidem due to insomnia. He increased the 
dosage from 10 mg to 500 mg daily after 3 
months. Not only was his insomnia not treated, 
but also he gradually became isolated, skeptical, 
and aggressive, laughed to himself, and dropped 
out of university. He was finally hospitalized in a 
psychiatric ward, and was treated for 2 months 
with risperidone 2 mg three times daily, 2 mg 
biperiden twice daily, trazodone 100 mg before 
sleeping, and gradual discontinuation of 
zolpidem. Patient’s sleep was regulated and 
zolpidem use reached zero. Positive symptoms of 
psychosis, such as hallucinations and delusions 
disappeared, but social and emotional 
relationships of the patient remain limited and 
impaired. He was discharged with the same 
treatment and the same condition. The patient 
was hospitalized again after 2 weeks (because of 
suspiciousness, fear of food poisoning, and refusal 
to eat), and electroconvulsive therapy (ECT) was 
added to risperidone, biperidin, and trazodone 
with mentioned  dosages . After 12 sessions of 
shock therapy the patient’s mood, thoughts, and 
emotions were relatively improved. Now, after 
three years, the patient is under care with 
diagnosis of chronic schizophrenia 
with  unfavorable response to treatment. 
Discussion 
High amounts of zolpidem are connected with 
protein in the body. Moreover, in people who 
have lower levels of albumin, like 
undernourished people, especially in association 
with the use of other drugs that are attached to 
albumin, it is possible that the amount of free 
zolpidem in the body increases.8 This results in 
more side effects in patients taking this drug. The 
effects of zolpidem on the central nervous system 
include headache, dizziness, nightmares, 
confusion and dizziness, drowsiness, sensory 
disorders in all senses, delirium, and complex 
behaviors such as sleepwalking and sleep eating. 
In one study, the incidence of illusion and 
hallucination was reported to be 0.3%.5,9,10-12  
In some studies, four factors have been 
reported to be effective on the increased risk of 
delirium or psychosis induced from zolpidem use, 
which include the use of this drug simultaneously 
with selective serotonin reuptake inhibitor 
medications, female gender, older age of the 
patient, and use of 10 mg or higher dosage of the 
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medication.11,13 Delirium and hallucination was 
not observed in 5 mg and lower doses.5,10 Another 
study reported a patient who had no history of 
psychosis, and due to the use of zolpidem had 
visual and auditory hallucinations and delusional 
thoughts. With withdrawal from zolpidem, these 
symptoms were resolved.14  
The patient in this study, due to the use of 
zolpidem in the initial dose for treating insomnia, 
gradually became dependent and addicted to 
high doses of zolpidem. Subsequently, this not 
only caused positive psychotic symptoms 
(delusions and hallucinations), but also negative 
symptoms (limitation of emotional and social 
relationships), and him dropping out of 
university. Furthermore, even with 
discontinuation of the drug, psychotic symptoms 
continued. This was unlike the reported cases, in 
which incidence of psychosis have been due to 
zolpidem use, was observed mostly in women, 
and was treat improved with the drug 
discontinuation. Even if it can be accepted that the 
positive symptoms of psychosis have been 
resolved with discontinuation of zolpidem, 
zolpidem has an important role in the occurrence 
and persistence of negative symptoms of 
psychosis. In other words, this rare case might be 
considered to be caused due to genetic differences 
and the potential risk of psychosis in different 
individuals which should be considered when 
prescribing zolpidem. In addition, in people who 
have high probability of drug abuse, if possible, it 
should not be used.  
Zolpidem is a relatively useful drug for 
improvement of sleep. Nevertheless, in the 
comprehensive treatment of patients, it is 
necessary to take into consideration the individual 
and family factors, such as genetic susceptibility 
and vulnerability to psychotic disorders, and the 
probability of drug abuse. 
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  زوﻟﭙﻴﺪم ﻣﺼﺮف ﺑﻴﺶ ﺑﻪ دﻧﺒﺎل ﭘﺎﻳﺪار ﺳﺎﻳﻜﻮز
  
  3ﻧﺼﻴﺮﻳﺎن ﻣﻨﺼﻮره دﻛﺘﺮ، 2ﺑﺎﺑﻚ ﺑﺮﻓﻪ ،1ﺷﻬﺮﺑﺎﺑﻜﻲ اﺳﻼﻣﻲ ﻣﻬﻴﻦ دﻛﺘﺮ
  
  
  ﭼﻜﻴﺪه
ﻫﺎي  ﺷﻮد. ﮔﺰارش ﺧﻮاﺑﻲ ﻣﻲ و ﺑﺎﻋﺚ درﻣﺎن ﺑﻲ ﻛﺮدهاﺛﺮ  Aﻫﺎي ﮔﺎﺑﺎ  زوﻟﭙﻴﺪم داروي ﻏﻴﺮ ﺑﻨﺰودﻳﺎزﭘﻴﻨﻲ اﺳﺖ ﻛﻪ ﺑﻪ ﻃﻮر اﻧﺘﺨﺎﺑﻲ ﺑﺮ ﮔﻴﺮﻧﺪه ﻣﻘﺪﻣﻪ:
  ﮔﺮدد. ﭘﺮﻳﺸﻲ( ﻣﺘﻌﺎﻗﺐ ﻣﺼﺮف زوﻟﭙﻴﺪم وﺟﻮد دارد ﻛﻪ ﺑﺎ ﻗﻄﻊ ﻣﺼﺮف آن ﺑﺮﻃﺮف ﻣﻲ ﻣﺘﻌﺪدي از ﺳﺎﻳﻜﻮز )روان
ﮔﺮم ﻗﺮار ﮔﺮﻓﺖ. وي در ﻃﻲ ﺳﻪ ﻣﺎه دوز  ﻣﻴﻠﻲ 01ﺧﻮاﺑﻲ ﺗﺤﺖ درﻣﺎن ﺑﺎ زوﻟﭙﻴﺪم ﺑﻪ ﻣﻴﺰان  ﻋﻠﺖ ﺑﻲﺳﺎﻟﻪ داﻧﺸﺠﻮي ﺣﻘﻮق ﺑﻪ  72ﻣﺮد  ﮔﺰارش ﻣﻮرد:
و ﺗﺮك  ﮔﺮدﻳﺪﮔﺮم اﻓﺰاﻳﺶ داد و ﻧﻪ ﺗﻨﻬﺎ ﻣﺸﻜﻞ ﺧﻮاﺑﺶ ﺑﺮﻃﺮف ﻧﺸﺪ، ﺑﻠﻜﻪ ﺑﻪ ﻃﻮر ﺗﺪرﻳﺠﻲ ﻣﻨﺰوي، ﺷﻜﺎك و ﭘﺮﺧﺎﺷﮕﺮ  ﻣﻴﻠﻲ 005زوﻟﭙﻴﺪم را ﺑﻪ 
ﺳﺎﻳﻜﻮﺗﻴﻚ و ﻗﻄﻊ ﺗﺪرﻳﺠﻲ زوﻟﭙﻴﺪم ﻗﺮار ﮔﺮﻓﺖ. ﺑﺪون ﺑﻬﺒﻮدي ﺳﺎﻳﻜﻮز  و ﺗﺤﺖ درﻣﺎن ﺑﺎ آﻧﺘﻲﭘﺰﺷﻜﻲ ﺑﺴﺘﺮي  ﺗﺤﺼﻴﻞ ﻛﺮد. ﺣﺪود دو ﻣﺎه در ﺑﺨﺶ روان
ﺳﺎﻳﻜﻮﺗﻴﻚ ﻗﺮار ﮔﺮﻓﺖ و ﺑﺎ ﺑﻬﺒﻮد ﻧﺴﺒﻲ  و ﺑﺎ ﺑﻬﺒﻮد وﺿﻌﻴﺖ ﺧﻮاب ﻣﺮﺧﺺ و ﺑﻌﺪ از دو ﻫﻔﺘﻪ دوﺑﺎره ﺑﺴﺘﺮي ﺷﺪ و ﺗﺤﺖ درﻣﺎن ﺑﺎ اﻟﻜﺘﺮوﺷﻮك و آﻧﺘﻲ
  ﺑﺎﺷﺪ. ﻴﺺ اﺳﻜﻴﺰوﻓﺮﻧﻴﺎ و ﺑﺎ ﺑﻬﺒﻮد ﻧﺴﺒﻲ ﺗﺤﺖ ﻣﺮاﻗﺒﺖ و درﻣﺎن ﻣﻲﻣﺮﺧﺺ ﮔﺮدﻳﺪ. در ﺣﺎل ﺣﺎﺿﺮ ﺑﻌﺪ از ﮔﺬﺷﺖ ﺳﻪ ﺳﺎل ﺑﺎ ﺗﺸﺨ
ﺟﺎﻣﻊ  زوﻟﭙﻴﺪم داروي ﺑﻪ ﻧﺴﺒﺖ ﻣﻔﻴﺪي ﺑﺮاي درﻣﺎن ﻣﺸﻜﻼت ﺧﻮاب ﺑﻪ وﻳﮋه ﺑﻬﺒﻮد ﺷﺮوع ﺧﻮاب اﺳﺖ. ﺑﻪ ﻫﺮ ﺣﺎل ﭘﺰﺷﻜﺎن و ﺑﺎﻟﻴﻨﮕﺮان در ﺑﺮﻧﺎﻣﻪ درﻣﺎﻧﻲ ﺑﺤﺚ:
  .ﺑﺎﺷﻨﺪﻪ ﺧﻮاﺑﻲ ﺑﺎﻳﺪ ﺑﻪ ﺷﺮاﻳﻂ، اﺳﺘﻌﺪاد، ﺳﺎﺑﻘﻪ ﻓﺮدي و ﺧﺎﻧﻮادﮔﻲ اﻧﻮاع ﺳﺎﻳﻜﻮز و ﺳﻮء ﻣﺼﺮف ﻣﻮاد و اﻟﻜﻞ ﺗﻮﺟﻪ ﺧﺎﺻﻲ داﺷﺘ ﺑﻴﻤﺎران داراي ﻣﺸﻜﻞ ﺑﻲ
  ﺧﻮاﺑﻲ ﺳﺎﻳﻜﻮز داﻳﻤﻲ و ﻣﻮﻗﺖ، ﺑﻲ زوﻟﭙﻴﺪم، واژﮔﺎن ﻛﻠﻴﺪي:
: (3-4) 6؛ 3931 ﻣﺠﻠﻪ اﻋﺘﻴﺎد و ﺳﻼﻣﺖ .زوﻟﭙﻴﺪم ﻣﺼﺮف ﺑﻴﺶ ﺑﻪ دﻧﺒﺎل ﭘﺎﻳﺪار ﺳﺎﻳﻜﻮز .ﻣﻨﺼﻮره ﺑﺎﺑﻚ، ﻧﺼﻴﺮﻳﺎن ﺑﺮﻓﻪ ﻣﻬﻴﻦ، ﺷﻬﺮﺑﺎﺑﻜﻲ اﺳﻼﻣﻲ ارﺟﺎع:
  .951-261
  39/3/51ﺗﺎرﻳﺦ ﭘﺬﻳﺮش:   39/1/9ﺗﺎرﻳﺦ درﻳﺎﻓﺖ: 
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